The Arora Report

Rss Facebook Twitter Linkedin

AKRO

DON’T MISS THE NEXT BIG BUYOUT — THE ARORA REPORT CELEBRATES 215 BUYOUTS

By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B.  RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases

Read More
October 27, 2025

CONGRATULATIONS! BIOTECH AKRO BUYOUT BY NVO BECOMES 213TH ARORA PORTFOLIO BUYOUT

By Nigam Arora NVO, the maker of weight loss drug Wegovy, is buying AKRO.  The deal is for $60 per share.  The deal consists of $54 per share in cash to be paid on closing and $6 per share in cash upon U.S. regulatory approval of efruxifermin drug cirrhosis. What To

Read More
October 9, 2025

9 Winners. 9 Losers. Gold, Silver & AI Trade Zones.

9 Winners. 9 Losers.
Gold, Silver & AI Trade Zones.

A new market cycle is forming.

AI, Metals &
Memory Playbook

See where sophisticated investors are positioning across software, precious metals, and AI memory.

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

Skip to content